Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma S.A. - American Depositary Shares (IPHA) 
Company Research Source: Business Wire
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndromeNew data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024The first patient was dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumorsIPH6501, Innate's proprietary ANKET® drug candidate, is being evaluated in a Phase 1/2 clinical trial in patients with B-cell non-Hodgkin's lymphomaInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9m investment from IFLI to support IPH6501 development in Follicular LymphomaCash position of €91.1 million1 as of December 31, 2024 with a cash horizon extended to mid 2026Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “C Show less Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IPHA alerts
Opt-in for
IPHA alerts

from News Quantified
Opt-in for
IPHA alerts

from News Quantified